Hsbc Holdings PLC Takes $171,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Hsbc Holdings PLC bought a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 18,773 shares of the biotechnology company’s stock, valued at approximately $171,000.

Several other institutional investors also recently bought and sold shares of ATXS. Quest Partners LLC lifted its holdings in shares of Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 2,861 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in Astria Therapeutics in the first quarter worth about $200,000. Panagora Asset Management Inc. grew its stake in shares of Astria Therapeutics by 104.7% during the second quarter. Panagora Asset Management Inc. now owns 30,926 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 15,816 shares during the last quarter. Finally, American International Group Inc. increased its holdings in shares of Astria Therapeutics by 49.4% during the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after acquiring an additional 8,122 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on ATXS shares. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Oppenheimer increased their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th. TD Cowen began coverage on Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Friday, September 27th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Astria Therapeutics currently has a consensus rating of “Buy” and an average target price of $25.20.

Astria Therapeutics Trading Up 5.0 %

Astria Therapeutics stock opened at $11.87 on Friday. The firm has a market cap of $651.82 million, a PE ratio of -5.12 and a beta of 0.71. The stock’s 50 day simple moving average is $11.30 and its two-hundred day simple moving average is $10.73. Astria Therapeutics, Inc. has a 12 month low of $4.26 and a 12 month high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). On average, equities research analysts forecast that Astria Therapeutics, Inc. will post -1.66 EPS for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.